NUVL
HealthcareNuvalent, Inc.
$97.98-0.02 (-0.02%)
Prev Close
$98.00
Open
$99.06
High
$101.82
Low
$96.06
Volume
488.4K
Market Cap
$7.40B
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Nuvalent, Inc. (NUVL) has been exclusively selling, with 0 insider purchases totaling $0.00 and 60 insider sales totaling $146.39M. The most recent insider transaction was by Porter James Richard (director, officer: President and CEO), who sold $2.97M worth of shares on Mar 10, 2026. Nuvalent, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $7.40B.
Buys (12M)
0
$0.00
Sells (12M)
60
$146.39M
Net Activity
Net Seller
$146.39M
Active Insiders
8
last 12 mo
NUVL Price Chart
NUVL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026↗ | Porter James Richard | director, officer: President and CEO | Sell | 30,000 | $98.99 | $2.97M | 341,294 |
| Mar 2, 2026↗ | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 5,500 | $103.05 | $566.8K | 62,436 |
| Mar 2, 2026↗ | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $103.03 | $566.7K | 60,617 |
| Feb 2, 2026↗ | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $102.08 | $561.4K | 63,428 |
| Jan 29, 2026↗ | Noci Darlene | Chief Development Officer | Sell | 5,500 | $102.08 | $561.4K | 0 |
| Jan 23, 2026↗ | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 15,000 | $110.15 | $1.65M | 59,634 |
| Jan 21, 2026↗ | Miller Deborah Ann | Chief Legal Officer | Sell | 15,000 | $110.15 | $1.65M | 0 |
| Jan 7, 2026↗ | Balcom Alexandra | officer: Chief Financial Officer | Sell | 7,417 | $97.25 | $721.3K | 88,279 |
| Jan 7, 2026↗ | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 6,952 | $97.26 | $676.2K | 48,189 |
| Jan 7, 2026↗ | Noci Darlene | officer: Chief Development Officer | Sell | 7,417 | $97.25 | $721.3K | 47,163 |
| Jan 7, 2026↗ | Pelish Henry E. | officer: Chief Scientific Officer | Sell | 5,160 | $97.24 | $501.8K | 70,535 |
| Jan 7, 2026↗ | Porter James Richard | director, officer: President and CEO | Sell | 27,433 | $97.26 | $2.67M | 302,383 |
| Jan 7, 2026↗ | Turner Christopher Durant | officer: Chief Medical Officer | Sell | 7,417 | $97.25 | $721.3K | 61,676 |
| Jan 5, 2026↗ | Balcom Alexandra | Chief Financial Officer | Sell | 7,417 | $97.25 | $721.3K | 0 |
| Jan 5, 2026↗ | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 16,952 | $99.18 | $1.68M | 55,081 |
| Jan 5, 2026↗ | Noci Darlene | Chief Development Officer | Sell | 7,417 | $97.25 | $721.3K | 0 |
| Jan 5, 2026↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 5,160 | $97.24 | $501.8K | 0 |
| Jan 5, 2026↗ | Porter James Richard | President and CEO | Sell | 27,433 | $97.26 | $2.67M | 0 |
| Jan 5, 2026↗ | Turner Christopher Durant | Chief Medical Officer | Sell | 7,417 | $97.25 | $721.3K | 0 |
| Jan 2, 2026↗ | Miller Deborah Ann | Chief Legal Officer | Sell | 10,000 | $100.51 | $1.01M | 0 |
| Dec 30, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $100.04 | $400.2K | 0 |
| Dec 8, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 7,084 | $110.32 | $781.5K | 0 |
| Nov 28, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $108.58 | $434.3K | 0 |
| Nov 24, 2025↗ | Flynn James E | Director | Sell | 742,574 | $95.45 | $70.88M | 0 |
| Nov 24, 2025↗ | Shair Matthew | Director | Sell | 7,500 | $109.37 | $820.3K | 0 |
| Nov 17, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 20,729 | $99.62 | $2.07M | 0 |
| Nov 17, 2025↗ | Miller Deborah Ann | Chief Legal Officer | Sell | 24,200 | $105.50 | $2.55M | 0 |
| Oct 30, 2025↗ | Miller Deborah Ann | Chief Legal Officer | Sell | 21,800 | $103.16 | $2.25M | 0 |
| Oct 30, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $102.92 | $411.7K | 0 |
| Oct 27, 2025↗ | Shair Matthew | Director | Sell | 60,000 | $100.26 | $6.02M | 0 |
| Oct 20, 2025↗ | Miller Deborah Ann | Chief Legal Officer | Sell | 5,000 | $94.91 | $474.6K | 0 |
| Oct 16, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $90.63 | $2.45M | 0 |
| Oct 15, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 1,683 | $85.57 | $144.0K | 0 |
| Oct 15, 2025↗ | Miller Deborah Ann | Chief Legal Officer | Sell | 28,000 | $90.72 | $2.54M | 0 |
| Oct 15, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 14,205 | $90.04 | $1.28M | 0 |
| Oct 13, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 40,000 | $87.36 | $3.49M | 0 |
| Oct 13, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 10,070 | $88.84 | $894.6K | 0 |
| Oct 1, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 20,000 | $85.48 | $1.71M | 0 |
| Sep 29, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 27,588 | $85.05 | $2.35M | 0 |
| Sep 29, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $83.07 | $332.3K | 0 |
| Sep 15, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $79.08 | $2.14M | 0 |
| Sep 10, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 3,725 | $78.83 | $293.6K | 0 |
| Aug 25, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $74.62 | $298.5K | 0 |
| Aug 15, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $75.42 | $2.04M | 0 |
| Aug 7, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 5,500 | $74.85 | $411.7K | 0 |
| Jul 30, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $80.36 | $321.4K | 0 |
| Jul 15, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 20,000 | $84.68 | $1.69M | 0 |
| Jul 15, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $82.27 | $2.22M | 0 |
| Jul 9, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 7,645 | $80.31 | $614.0K | 0 |
| Jun 27, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 20,000 | $80.02 | $1.60M | 0 |
| Jun 26, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $78.71 | $314.8K | 0 |
| Jun 25, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 10,800 | $79.88 | $862.7K | 0 |
| Jun 16, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $76.93 | $2.08M | 0 |
| Jun 6, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 200 | $79.82 | $16.0K | 0 |
| May 29, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $71.31 | $285.2K | 0 |
| May 15, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $69.60 | $1.88M | 0 |
| Apr 29, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $74.56 | $298.2K | 0 |
| Apr 15, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $68.94 | $1.86M | 0 |
| Mar 27, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $73.12 | $292.5K | 0 |
| Mar 17, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $75.87 | $2.05M | 0 |
| Mar 6, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 34,000 | $71.87 | $2.44M | 0 |
| Feb 24, 2025↗ | Shair Matthew | Director | Sell | 2,000 | $78.43 | $156.9K | 0 |
NUVL Insider Buying Activity
The following table shows recent insider purchases of Nuvalent, Inc. (NUVL) stock reported via SEC Form 4 filings.
No insider buying activity found for NUVL in the last 12 months.
NUVL Insider Selling Activity
The following table shows recent insider sales of Nuvalent, Inc. (NUVL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026↗ | Porter James Richard | director, officer: President and CEO | Sell | 30,000 | $98.99 | $2.97M | 341,294 |
| Mar 2, 2026↗ | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 5,500 | $103.05 | $566.8K | 62,436 |
| Mar 2, 2026↗ | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $103.03 | $566.7K | 60,617 |
| Feb 2, 2026↗ | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $102.08 | $561.4K | 63,428 |
| Jan 29, 2026↗ | Noci Darlene | Chief Development Officer | Sell | 5,500 | $102.08 | $561.4K | 0 |
| Jan 23, 2026↗ | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 15,000 | $110.15 | $1.65M | 59,634 |
| Jan 21, 2026↗ | Miller Deborah Ann | Chief Legal Officer | Sell | 15,000 | $110.15 | $1.65M | 0 |
| Jan 7, 2026↗ | Balcom Alexandra | officer: Chief Financial Officer | Sell | 7,417 | $97.25 | $721.3K | 88,279 |
| Jan 7, 2026↗ | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 6,952 | $97.26 | $676.2K | 48,189 |
| Jan 7, 2026↗ | Noci Darlene | officer: Chief Development Officer | Sell | 7,417 | $97.25 | $721.3K | 47,163 |
| Jan 7, 2026↗ | Pelish Henry E. | officer: Chief Scientific Officer | Sell | 5,160 | $97.24 | $501.8K | 70,535 |
| Jan 7, 2026↗ | Porter James Richard | director, officer: President and CEO | Sell | 27,433 | $97.26 | $2.67M | 302,383 |
| Jan 7, 2026↗ | Turner Christopher Durant | officer: Chief Medical Officer | Sell | 7,417 | $97.25 | $721.3K | 61,676 |
| Jan 5, 2026↗ | Balcom Alexandra | Chief Financial Officer | Sell | 7,417 | $97.25 | $721.3K | 0 |
| Jan 5, 2026↗ | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 16,952 | $99.18 | $1.68M | 55,081 |
| Jan 5, 2026↗ | Noci Darlene | Chief Development Officer | Sell | 7,417 | $97.25 | $721.3K | 0 |
| Jan 5, 2026↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 5,160 | $97.24 | $501.8K | 0 |
| Jan 5, 2026↗ | Porter James Richard | President and CEO | Sell | 27,433 | $97.26 | $2.67M | 0 |
| Jan 5, 2026↗ | Turner Christopher Durant | Chief Medical Officer | Sell | 7,417 | $97.25 | $721.3K | 0 |
| Jan 2, 2026↗ | Miller Deborah Ann | Chief Legal Officer | Sell | 10,000 | $100.51 | $1.01M | 0 |
| Dec 30, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $100.04 | $400.2K | 0 |
| Dec 8, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 7,084 | $110.32 | $781.5K | 0 |
| Nov 28, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $108.58 | $434.3K | 0 |
| Nov 24, 2025↗ | Flynn James E | Director | Sell | 742,574 | $95.45 | $70.88M | 0 |
| Nov 24, 2025↗ | Shair Matthew | Director | Sell | 7,500 | $109.37 | $820.3K | 0 |
| Nov 17, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 20,729 | $99.62 | $2.07M | 0 |
| Nov 17, 2025↗ | Miller Deborah Ann | Chief Legal Officer | Sell | 24,200 | $105.50 | $2.55M | 0 |
| Oct 30, 2025↗ | Miller Deborah Ann | Chief Legal Officer | Sell | 21,800 | $103.16 | $2.25M | 0 |
| Oct 30, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $102.92 | $411.7K | 0 |
| Oct 27, 2025↗ | Shair Matthew | Director | Sell | 60,000 | $100.26 | $6.02M | 0 |
| Oct 20, 2025↗ | Miller Deborah Ann | Chief Legal Officer | Sell | 5,000 | $94.91 | $474.6K | 0 |
| Oct 16, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $90.63 | $2.45M | 0 |
| Oct 15, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 1,683 | $85.57 | $144.0K | 0 |
| Oct 15, 2025↗ | Miller Deborah Ann | Chief Legal Officer | Sell | 28,000 | $90.72 | $2.54M | 0 |
| Oct 15, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 14,205 | $90.04 | $1.28M | 0 |
| Oct 13, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 40,000 | $87.36 | $3.49M | 0 |
| Oct 13, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 10,070 | $88.84 | $894.6K | 0 |
| Oct 1, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 20,000 | $85.48 | $1.71M | 0 |
| Sep 29, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 27,588 | $85.05 | $2.35M | 0 |
| Sep 29, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $83.07 | $332.3K | 0 |
| Sep 15, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $79.08 | $2.14M | 0 |
| Sep 10, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 3,725 | $78.83 | $293.6K | 0 |
| Aug 25, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $74.62 | $298.5K | 0 |
| Aug 15, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $75.42 | $2.04M | 0 |
| Aug 7, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 5,500 | $74.85 | $411.7K | 0 |
| Jul 30, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $80.36 | $321.4K | 0 |
| Jul 15, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 20,000 | $84.68 | $1.69M | 0 |
| Jul 15, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $82.27 | $2.22M | 0 |
| Jul 9, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 7,645 | $80.31 | $614.0K | 0 |
| Jun 27, 2025↗ | Balcom Alexandra | Chief Financial Officer | Sell | 20,000 | $80.02 | $1.60M | 0 |
| Jun 26, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $78.71 | $314.8K | 0 |
| Jun 25, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 10,800 | $79.88 | $862.7K | 0 |
| Jun 16, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $76.93 | $2.08M | 0 |
| Jun 6, 2025↗ | Pelish Henry E. | Chief Scientific Officer | Sell | 200 | $79.82 | $16.0K | 0 |
| May 29, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $71.31 | $285.2K | 0 |
| May 15, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $69.60 | $1.88M | 0 |
| Apr 29, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $74.56 | $298.2K | 0 |
| Apr 15, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $68.94 | $1.86M | 0 |
| Mar 27, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 4,000 | $73.12 | $292.5K | 0 |
| Mar 17, 2025↗ | Porter James Richard | President and CEO | Sell | 27,000 | $75.87 | $2.05M | 0 |
| Mar 6, 2025↗ | Noci Darlene | Chief Development Officer | Sell | 34,000 | $71.87 | $2.44M | 0 |
| Feb 24, 2025↗ | Shair Matthew | Director | Sell | 2,000 | $78.43 | $156.9K | 0 |
NUVL Insiders
Similar Stocks to NUVL
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$538.00+0.97%
$21.50B
INCY
Incyte Corporation
$92.25+0.27%
$20.10B
RVMD
Revolution Medicines, Inc.
$95.44+0.39%
$20.10B
MRNA
Moderna, Inc.
$52.38-1.89%
$19.96B